As of the latest Form 4 filed Jun 18, 2026.
What Dianthus Therapeutics Inc. insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 49 most recent filings for DNTH.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-18 | 2026-06-17 | Veness Adam M SVP, General Counsel and Sec. | SSale | −13.2K | $81.38 | $1.08M | Yes (planned) | Form 4 ↗ |
| 2026-06-18 | 2026-06-17 | Veness Adam M, SVP, General Counsel and Sec. | SSale | −16.8K | $80.34 | $1.35M | Yes (planned) | Form 4 ↗ |
| 2026-06-18 | 2026-06-17 | Veness Adam M, SVP, General Counsel and Sec. | MExercise | +30.0K | $17.88 | $536K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Randhawa Simrat EVP, Head of R&D | SSale | −4.16K | $91.37 | $380K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Randhawa Simrat, EVP, Head of R&D | SSale | −16.9K | $90.72 | $1.54M | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Randhawa Simrat, EVP, Head of R&D | SSale | −5.43K | $89.72 | $487K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Randhawa Simrat, EVP, Head of R&D | MExercise | +9.38K | $22.07 | $207K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Randhawa Simrat, EVP, Head of R&D | MExercise | +6.25K | $21.77 | $136K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Randhawa Simrat, EVP, Head of R&D | MExercise | +6.91K | $17.88 | $124K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Randhawa Simrat, EVP, Head of R&D | MExercise | +4.00K | $8.44 | $33.7K | Yes (planned) | Form 4 ↗ |
| 2026-05-11 | 2026-05-08 | Soteropoulos Paula Director | SSale | −599.00 | $85.47 | $51.2K | Yes (planned) | Form 4 ↗ |
| 2026-05-11 | 2026-05-08 | Soteropoulos Paula, Director | MExercise | +599.00 | $8.44 | $5.06K | Yes (planned) | Form 4 ↗ |
| 2026-04-10 | 2026-04-09 | Savitz Ryan EVP, CFO & CBO | SSale | −8.22K | $89.84 | $739K | Yes (planned) | Form 4 ↗ |
| 2026-04-10 | 2026-04-09 | Savitz Ryan, EVP, CFO & CBO | MExercise | +8.22K | $17.88 | $147K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Savitz Ryan EVP, CFO & CBO | SSale | −7.23K | $85.54 | $619K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Savitz Ryan, EVP, CFO & CBO | SSale | −19.5K | $84.57 | $1.65M | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Savitz Ryan, EVP, CFO & CBO | SSale | −59.8K | $83.90 | $5.02M | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Savitz Ryan, EVP, CFO & CBO | SSale | −2.37K | $82.84 | $196K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Savitz Ryan, EVP, CFO & CBO | SSale | −800.00 | $81.36 | $65.1K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Savitz Ryan, EVP, CFO & CBO | SSale | −1.49K | $80.25 | $119K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Savitz Ryan, EVP, CFO & CBO | SSale | −21.8K | $78.86 | $1.72M | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Savitz Ryan, EVP, CFO & CBO | SSale | −1.39K | $78.33 | $109K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Savitz Ryan, EVP, CFO & CBO | MExercise | +40.0K | $17.88 | $715K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Savitz Ryan, EVP, CFO & CBO | MExercise | +74.4K | $8.44 | $628K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Soteropoulos Paula Director | SSale | −599.00 | $80.11 | $48.0K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Soteropoulos Paula, Director | MExercise | +599.00 | $8.44 | $5.06K | Yes (planned) | Form 4 ↗ |
| 2026-03-26 | 2026-03-24 | Soteropoulos Paula Director | SSale | −27.6K | $78.05 | $2.15M | Yes (planned) | Form 4 ↗ |
| 2026-03-26 | 2026-03-24 | Soteropoulos Paula, Director | MExercise | +27.6K | $8.44 | $233K | Yes (planned) | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | Garcia Marino CEO AND PRESIDENT | MExercise | +5.59K | $17.88 | $100.0K | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | Garcia Marino, CEO AND PRESIDENT | MExercise | +59.7K | $6.70 | $400K | No | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | Randhawa Simrat EVP, Head of R&D | SSale | −33.8K | $81.48 | $2.76M | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | Randhawa Simrat, EVP, Head of R&D | MExercise | +12.5K | $22.07 | $276K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | Randhawa Simrat, EVP, Head of R&D | MExercise | +8.33K | $21.77 | $181K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | Randhawa Simrat, EVP, Head of R&D | MExercise | +5.00K | $17.88 | $89.4K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | Randhawa Simrat, EVP, Head of R&D | MExercise | +8.00K | $8.44 | $67.5K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | Garcia Marino CEO AND PRESIDENT | SSale | −900.00 | $85.53 | $77.0K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | Garcia Marino, CEO AND PRESIDENT | SSale | −200.00 | $83.38 | $16.7K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | Garcia Marino, CEO AND PRESIDENT | SSale | −12.8K | $82.60 | $1.06M | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | Garcia Marino, CEO AND PRESIDENT | SSale | −65.5K | $81.74 | $5.36M | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | Garcia Marino, CEO AND PRESIDENT | SSale | −43.5K | $80.69 | $3.51M | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | Garcia Marino, CEO AND PRESIDENT | MExercise | +123K | $6.70 | $824K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | SSale | −300.00 | $85.53 | $25.7K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | CARR EDWARD, CHIEF ACCOUNTING OFFICER | SSale | −200.00 | $83.38 | $16.7K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | CARR EDWARD, CHIEF ACCOUNTING OFFICER | SSale | −3.87K | $82.66 | $319K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | CARR EDWARD, CHIEF ACCOUNTING OFFICER | SSale | −23.5K | $81.75 | $1.92M | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | CARR EDWARD, CHIEF ACCOUNTING OFFICER | SSale | −15.9K | $80.71 | $1.28M | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | CARR EDWARD, CHIEF ACCOUNTING OFFICER | MExercise | +10.0K | $21.77 | $218K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | CARR EDWARD, CHIEF ACCOUNTING OFFICER | MExercise | +17.5K | $22.07 | $386K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-12 | CARR EDWARD, CHIEF ACCOUNTING OFFICER | MExercise | +16.2K | $17.88 | $289K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also DNTH’s full analysis or the market-wide insider trading feed. The tabs above jump to DNTH’s other SEC data.
Source: SEC Form 4 filings for DNTH, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.